Medicare Enrolled
Dr. John Bartnik, M.D.
Hematology & Oncology · Saginaw, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Bartnik from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bartnik?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bartnik
Dr. John Bartnik is a hematology & oncology specialist in Saginaw, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Bartnik performed 13,918 Medicare services across 1,682 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bartnik received a total of $5,981 from 55 pharmaceutical and/or device companies across 254 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bartnik is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 20% volume in MI
$5,981 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,918
Medicare services
Top 20% in MI for hematology & oncology
1,682
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~696 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,000 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,948 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
739 | $8 | $20 |
| Anti-nausea injection (ondansetron/Zofran) | 738 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
584 | $91 | $199 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
502 | $21 | $100 |
| Anti-nausea injection (Aloxi/palonosetron) | 500 | $1 | $10 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
410 | $10 | $25 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
350 | $8 | $10 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
310 | $98 | $250 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
222 | $2 | $27 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
194 | $62 | $150 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
135 | $11 | $40 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
130 | $19 | $63 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
124 | $1 | $2 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
120 | $11 | $80 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
108 | $7 | $57 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
94 | $48 | $175 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
75 | $21 | $55 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
73 | $16 | $50 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
65 | $120 | $240 |
| Injection, lorazepam, 2 mg | 52 | $1 | $2 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
50 | $8 | $50 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
50 | $1 | $20 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
46 | $16 | $65 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
43 | $1 | $5 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
38 | $133 | $325 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
37 | $6 | $10 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
37 | $1 | $10 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
34 | $45 | $160 |
| Iron level test | 18 | $6 | $15 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
18 | $9 | $18 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
18 | $103 | $180 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
15 | $66 | $150 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
14 | $13 | $25 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
14 | $28 | $92 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
13 | $70 | $125 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
7.1% high complexity
72.4% medium
20.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,981
Total received (2018-2024)
Avg $854/year across 7 years
Top 28% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
254
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,717 (78.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,264 (21.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$715
2023
$980
2022
$111
2021
$194
2020
$495
2019
$1,259
2018
$2,227
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$122
Exelixis Inc.
$100
Eisai Inc.
$75
Astellas Pharma US Inc
$72
Genentech USA, Inc.
$71
Janssen Biotech, Inc.
$53
PFIZER INC.
$41
Daiichi Sankyo Inc.
$40
GlaxoSmithKline, LLC.
$24
Myriad Genetic Laboratories, Inc.
$22
E.R. Squibb & Sons, L.L.C.
$22
Blueprint Medicines Corporation
$21
Merck Sharp & Dohme LLC
$19
Gilead Sciences, Inc.
$18
Apellis Pharmaceuticals, Inc.
$14
Top 3 companies account for 41.6% of 2024 payments
All-time payments by company (2018-2024) ›
Tosoh Bioscience, Inc.
$1,084
Novartis Pharmaceuticals Corporation
$577
Genentech USA, Inc.
$555
Janssen Biotech, Inc.
$543
PFIZER INC.
$358
Exelixis Inc.
$315
Amgen Inc.
$273
E.R. Squibb & Sons, L.L.C.
$165
Celgene Corporation
$159
Merck Sharp & Dohme Corporation
$148
Lilly USA, LLC
$136
AstraZeneca Pharmaceuticals LP
$119
Eisai Inc.
$111
Janssen Products, LP
$100
GENZYME CORPORATION
$96
Astellas Pharma US Inc
$94
AVEO Pharmaceuticals, Inc.
$94
Gilead Sciences, Inc.
$93
Taiho Oncology, Inc.
$64
Takeda Pharmaceuticals U.S.A., Inc.
$59
Daiichi Sankyo Inc.
$50
EMD Serono, Inc.
$48
Janssen Scientific Affairs, LLC
$47
Merck Sharp & Dohme LLC
$37
AbbVie, Inc.
$36
Seagen Inc.
$36
Kite Pharma, Inc.
$34
Seattle Genetics, Inc.
$33
Apellis Pharmaceuticals, Inc.
$32
Regeneron Healthcare Solutions, Inc.
$30
Jazz Pharmaceuticals Inc.
$29
Array BioPharma Inc.
$28
INSYS Therapeutics Inc
$27
Foundation Medicine, Inc.
$25
GlaxoSmithKline, LLC.
$24
Myriad Genetic Laboratories, Inc.
$22
PharmaEssentia USA Corporation
$22
JAZZ PHARMACEUTICALS INC.
$21
Blueprint Medicines Corporation
$21
Dova Pharmaceuticals
$21
BeiGene USA, Inc.
$20
EISAI INC.
$18
Pharmacyclics LLC, An AbbVie Company
$18
Bayer HealthCare Pharmaceuticals Inc.
$17
Clovis Oncology, Inc.
$15
Teva Pharmaceuticals USA, Inc.
$15
Advanced Accelerator Applications
$14
Janssen Pharmaceuticals, Inc
$14
G1 Therapeutics, Inc.
$13
ARRAY BIOPHARMA INC
$13
Secura Bio, Inc.
$12
Deciphera Pharmaceuticals Inc.
$12
Kyowa Kirin, Inc.
$12
Epizyme, Inc.,
$12
TerSera Therapeutics LLC
$11
Top 3 companies account for 37.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AIA-PACK · ALIMTA · AYVAKIT · Alecensa · Avastin · B12 · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · Doptelet · ELITEK · ENHERTU · ENJAYMO · ERLEADA · Empaveli · Enhertu · Erleada · FARYDAK · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · IBRANCE · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MYLOTARG · MYRISK · NINLARO · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · PADCEV · PIQRAY · POTELIGEO · PROMACTA · PROSTATE CANCER - DISEASE · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SCEMBLIX · SUTENT · SYNDROS · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TUKYSA · Tecentriq · Trodelvy · VENCLEXTA · VOTRIENT · VYXEOS · Venclexta · XALKORI · XARELTO · XTANDI · Xospata · Yescarta · ZEPZELCA · ZOLADEX · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (79%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
9
Per 100K population
4.8
County median income
$58,347
Nearest hospital
HEALTHSOURCE SAGINAW
4.1 mi
4.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Bartnik is a mixed practice specialist, with above-average Medicare volume (top 20% in MI), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Bartnik experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Bartnik performed 6,000 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bartnik receive payments from pharmaceutical companies?
Yes. Dr. Bartnik received a total of $5,981 from 55 companies across 254 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bartnik's costs compare to other hematology & oncology specialists in Saginaw?
Dr. Bartnik's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bartnik) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Saginaw
Browse hematology & oncology specialists in Saginaw ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MI
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MI
Which MI hematology & oncology specialists receive the most from drug and device companies.
By company
Tosoh Bioscience, Inc. Payments to Doctors
See all physicians who received payments from Tosoh Bioscience, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology